0001209191-19-003643.txt : 20190114
0001209191-19-003643.hdr.sgml : 20190114
20190114194453
ACCESSION NUMBER: 0001209191-19-003643
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190110
FILED AS OF DATE: 20190114
DATE AS OF CHANGE: 20190114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schall Thomas J.
CENTRAL INDEX KEY: 0001423084
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 19526002
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-10
0
0001340652
ChemoCentryx, Inc.
CCXI
0001423084
Schall Thomas J.
C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW
CA
94043
1
1
0
0
President and CEO
Common Stock
2019-01-10
4
M
0
36762
6.00
A
2265617
D
Common Stock
2019-01-10
4
S
0
36762
12.1618
D
2228855
D
Stock Option (right to buy)
6.00
2019-01-10
4
M
0
36762
D
2009-07-29
2019-07-29
Common Stock
36762
160000
D
Shares sold are associated with stock options that will expire in July 2019.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $12.00 to $12.43 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
As of January 10, 2019, and prior to this transaction, the exercised options were fully vested.
Not applicable.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2019-01-14